Journal
NATURE MEDICINE
Volume 16, Issue 11, Pages 1227-1232Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2222
Keywords
-
Funding
- Taube-Koret Center for Huntington's Disease Research
- NIH - National Institute of Neurological Disorders and Stroke [2R01 NS039074, 2R01 NS045091]
- NIH - National Institute on Aging [2P01 AG022074]
- J. David Gladstone Institute
Ask authors/readers for more resources
Neurodegenerative diseases are the sixth leading cause of death in the US. The market for disease-modifying drugs is enormous, but no drug exists. Academic scientists are increasingly pursuing the discovery and development of therapeutics. Their progress could potentially reduce the risk of failure sufficiently to warrant greater industry investment and movement of leads into clinical trials. Here we consider the many obstacles to the development of therapeutics for neurodegenerative disease within academia, with a special focus on organizational issues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available